Last edited by Gokazahn
Tuesday, October 20, 2020 | History

3 edition of Novel therapeutic targets for anti-arrhythmic drugs found in the catalog.

Novel therapeutic targets for anti-arrhythmic drugs

Novel therapeutic targets for anti-arrhythmic drugs

  • 388 Want to read
  • 0 Currently reading

Published by John Wiley & Sons in Hoboken, N.J .
Written in English

    Subjects:
  • Myocardial depressants,
  • Arrhythmia -- Chemotherapy,
  • Anti-Arrhythmia Agents,
  • Arrhythmias, Cardiac -- drug therapy

  • Edition Notes

    Includes bibliographical references and index.

    Statement[edited by] George E. Billman.
    ContributionsBillman, George E.
    Classifications
    LC ClassificationsRM347 .N68 2010
    The Physical Object
    Paginationp. ;
    ID Numbers
    Open LibraryOL23392166M
    ISBN 109780470261002
    LC Control Number2009020796

    George Edward Billman (born J ) is an American physiologist and professor at Ohio State receiving a Ph.D from the University of Kentucky in , Billman began his professional career at the University of , he joined the Ohio State staff, where he became an associate professor in and a full professor in   The RAAFT-2 (Radiofrequency Ablation vs. Anti-arrhythmic Drugs as First-Line Treatment of Symptomatic Atrial Fibrillation) trial was designed to assess whether RF catheter-based PVI is superior to AADs as first-line therapy in patients with symptomatic paroxysmal recurrent AF not previously treated with therapeutic doses of AADs.

    Title: Pharmacology of Cardiac Potassium Channels: Li, GR Dong, MQ. Keywords: Antiarrhythmic drugs. Table of Contents Novem - Volume , Issue suppl_1: Abstracts From the American Heart Association's Scientific Sessions and Resuscitation Science Symposium.

      While drugs targeting the RAAS represent the cornerstone of HF treatment, there is a need for novel therapeutic approaches. LCZ is an effective and safe alternative to ACE inhibitors and may change future first-line approaches to HF therapy because of its significant improvement in survival and reduced rates of : Juan Tamargo. Anti arrhythmic drugs See more. may mean new therapeutic targets for treating Alzheimer’s disease. Role of NMDA Receptors in Tolerance and Dependence - Health tips Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA glutamate receptors pins.


Share this book
You might also like
Congress and the budget

Congress and the budget

Issues in the tax treatment of international interest rate and currency swap transactions

Issues in the tax treatment of international interest rate and currency swap transactions

Investment Us profit from China

Investment Us profit from China

Heads and tales

Heads and tales

sketch of war

sketch of war

Old Paris

Old Paris

A Bill for the Better Organization of the General Staff of the Army of the United States

A Bill for the Better Organization of the General Staff of the Army of the United States

Health promotion throughout the life span

Health promotion throughout the life span

Park walking in San Diego County

Park walking in San Diego County

[Squash

[Squash

Interior, Environment, and Related Agencies Appropriations for 2006

Interior, Environment, and Related Agencies Appropriations for 2006

Alfred Tennyson.

Alfred Tennyson.

Common Hongkong ferns

Common Hongkong ferns

The mating season

The mating season

vacancy

vacancy

Novel therapeutic targets for anti-arrhythmic drugs Download PDF EPUB FB2

Get this from a library. Novel therapeutic targets for anti-arrhythmic drugs. [George Edward Billman;] -- Profiles potential treatment approaches for cardiac arrhythmias.

Cardiac arrhythmias of ventricular origin are responsible for the deaths of nearly half a million Americans each year while atrial. Request PDF | Novel Therapeutic Targets for Antiarrhythmic Drugs | Introduction Effects of K+ Channel Blockade on APD and Arrhythmogenesis Conclusions/Future Directions References | Find, read and.

Considerable work has been performed to improve medical options but treatment success still remains suboptimal. The use of conventional anti-arrhythmic agents has been limited by potentially fatal ventricular proarrhythmia.

Thus, novel drug targets have been characterised and are currently being tested in experimental and clinical studies. Schiöth and colleagues examine the drugs approved by the US Food and Drug Administration over the past 30 years and analyse the interactions of these drugs with therapeutic targets encoded by the Cited by: Novel Therapeutic Targets for Antiarrhythmic Drugs to the development and deployment of antiarrhythmic drugs, and this book is an admirable attempt to find a way.

were free from AF. Considerable work has been performed to improve medical options but treatment success still remains suboptimal. The use of conventional anti-arrhythmic agents has been limited by potentially fatal ventricular proarrhythmia. Thus, novel drug targets have been characterised and are currently being tested in experimental and clinical by: targets, cellular mechanisms, functional targets, and clinical arrhythmias for individual drugs with similari-ties and differences in their effects, accommodating their multiple actions.

Although not then seeking a completed formal classification system, it furnished an accurate and comprehensive updated analysis of anti-arrhythmic drugs.

SciTech Book News: Article Type: Brief article: Date: Mar 1, Words: Previous Article: Introduction to counselling survivors of interpersonal trauma. Next Article: Novel therapeutic targets for anti-arrhythmic drugs. Topics. Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.

Many attempts have been made to classify antiarrhythmic agents. The problem arises from the fact that many of the. It also explores sex differences in prevalent diseases, genetics-based therapeutic strategies and the use of various animal models and alternatives.

The book is intended for research scientists and clinical scientists in the cardiovascular field, human geneticists and cardiologists. Billman was the editor of the book Novel Therapeutic Targets for Antiarrhythmic Drugs published by John Wiley and Sons, and contributed three chapters to it.

According to the publisher, the book describes the state of cardiac arrhythmia treatment, and future directions the research may : Fellow – American Heart Association (). Prof. Naccarelli has published over peer reviewed papers, book chapters and reviews in addition to authoring four books related to cardiac arrhythmia.

He is currently on the steering committee of multiple clinical trials and has vast experience in the development and approval of. Thus these drugs selectively suppress automaticity and slow conduction velocity in ischemic and diseased ventricular myocardium.

(anti-arrhythmic class I) and prolongation of the action potential duration (anti-arrhythmic class III). In conclusion, Endothelial SKCa channels may represent novel therapeutic targets for the treatment of. However, the proarrhythmic effect of the anti-arrhythmic drugs has been causing concerns on the safety of the arrhythmic patients.

As a complementary and alternative medicine, Chinese medicine plays an increasing role in the treatment of arrhythmias (Dong et al., ).Cited by: 1.

Cardiac Na+ Channels as Therapeutic Targets for Antiarrhythmic Agents. Authors; Rivolta I, Motoike HK, Memmi M, Napolitano C, Priori SG, Kass RS () Novel arrhythmogenic mechanism revealed by a Long-QT syndrome mutation in the cardiac Na+ channel. Wit AL () Electropharmacology of anti-arrhythmic drugs.

Am Heart J – Cited by: Indeed, drugs affecting intracellular Ca 2+ handling have the ability to decrease automaticity of Ca 2+ related AP generation and have emerging uses as anti-arrhythmic agents.

Classical drugs that target proteins responsible for cellular Ca 2+-handling include β-blockers (inhibitor of β-AR activation), and the LTCC inhibitors verapamil and Cited by: 1. Frank J. Dowd, in Pharmacology and Therapeutics for Dentistry (Seventh Edition), Drug Interactions.

Antiarrhythmic drugs can participate in a wide variety of drug interactions. Because the margin of safety with these drugs as a group is narrow, clinically significant interactions may develop whenever the activity or plasma concentration of an antiarrhythmic agent is altered.

INTRODUCTION. Hypertension is an asymptomatic condition of persistently elevated blood pressure (BP) that affects approximately 50 million Americans and one billion people worldwide. 1, 2 It has been associated with other diseases and events such as myocardial infarction (MI), heart failure, stroke, and kidney disease.

1 Although hypertension the most common primary care diagnosis in the U.S Cited by: Selecting a short list of landmark basic science and epidemiology papers in the field of cardiac electrophysiology for this chapter has been no easy task. For every paper listed in the following section, we have had to leave out several other equally important, high-impact papers.

To help narrow down the list, we have had to come up with a restrictive definition of what makes a landmark paper. Therefore, further intensive research using disease-specific hiPSC-CMs should be promoted to gain insights into the underlying mechanisms and to identify potential therapeutic targets of these genetic diseases in order to develop novel therapeutic approaches for individual patients.

Human Induced Pluripotent Stem Cells as a Tool for Drug ScreeningAuthor: Shu Nakao, Dai Ihara, Koji Hasegawa, Teruhisa Kawamura. Novel therapeutic agents for macromolecular structures The structural targets which bind these ligands include targets on or in endogenous mammalian cells (e.g., cancer cells) or targets on exogenous microbes containing macromolecular structures (e.g., viruses, fungi, bacteria, parasites, etc.).

[] Accordingly, drugs which mediate.Omega-3 polyunsaturated fatty acids (PUFAs), namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are permanent subjects of interest in relation to the protection of cardiovascular health and the prevention of the incidence of both ventricular and atrial arrhythmias.

The purpose of this updated review is to focus on the novel cellular and molecular effects of omega-3 Cited by: The result is an expanded but pragmatic classification that encompasses approved and potential anti-arrhythmic drugs.

This will aid our understanding and clinical management of cardiac arrhythmias and facilitate future therapeutic developments. It starts by considering the range of pharmacological targets, and tracks these to their particular.